Background: Hepatic steatosis is strongly associated with insulin resistance. It has been reported that G 0 /G 1 switch gene 2 (G0s2) inhibits the lipolytic activity of adipose triglyceride lipase, which is a major lipase in the liver as well as in adipocytes. Moreover, G0s2 protein content is increased in the livers of highfat diet (HFD)-fed rats. In the present study, we investigated the effect of hepatic G0s2 on insulin sensitivity in male Wistar rats. Methods: Male Wistar rats were fed a 60% HFD for 4 weeks. After 3 weeks of feeding, rats were injected with adenovirus-expressing green fluorescent protein (Ad-GFP; control) or adenovirus-expressing mouse G0s2 (Ad-G0s2). On Day 7 after injection, a euglycemic-hyperinsulinemic clamp study was performed in rats fasted for 8 h. Results: Body weight and fasting glucose levels were not significantly different between the Ad-GFP and Ad-G0s2 groups. During the clamp study, the glucose infusion rate required for euglycemia decreased significantly by 16% in the Ad-G0s2 compared with Ad-GFP group. The insulin-suppressed hepatic glucose output increased significantly in the Ad-G0s2 group, but the insulinstimulated glucose disposal rate was not significantly different between the two groups. Consistent with the clamp data, insulin-stimulated phosphorylation of Akt decreased significantly in livers of rats injected with Ad-G0s2. Furthermore, Oil Red O-staining indicated that overexpression of G0s2 protein in the liver promoted hepatic steatosis by 2.5-fold in HFD-fed rats.
Introduction
Hepatic steatosis, defined as ectopic accumulation of triglycerides in hepatocytes, is the first step in the spectrum of non-alcoholic fatty liver disease (NAFLD). In the "two-hit" model of NAFLD pathogenesis, hepatic fat accumulation is the "first hit" and hepatic steatosis leads to the "second hit", which results in hepatocyte injury. 1 Hepatic steatosis is more frequent among subjects with obesity, type 2 diabetes, or metabolic syndrome, 2, 3 and the prevalence of hepatic steatosis has been increasing in Japan. 4 Accumulation of triglycerides in the liver leads to hepatic insulin resistance; 5 moreover, hepatic steatosis is thought to be an independent determinant of cardiovascular disease. 6, 7 Hepatic steatosis develops when free fatty acid uptake and synthesis in the liver exceeds its elimination. 8 Numerous molecules can be involved in the regulation of lipid metabolism in the liver.
The G 0 /G 1 switch gene 2 (G0s2) is one of the G 0 /G 1 switch genes that were first identified in lymphocytes during their lectin-activated switch from the G 0 to the G 1 phase of the cell cycle. 9 Several reports have suggested that G0s2 is a multifaceted protein with disparate functions related to proliferation, metabolism, inflammation, and carcinogenesis. The G0s2 gene is epigenetically silenced in head and neck cancer, 10 squamous cell lung cancer, and cisplatin-resistant cancer cells. 11 Conversely, G0s2 expression is elevated in endometriosis, 12 bronchial epithelial cells treated with retinoic acid, 13 senescent dermal fibroblasts, 14 bone marrow cells from patients with rheumatoid arthritis, 15 and peripheral mononuclear cells from patients with vasculitis 16 and psoriasis. 17 Later, G0s2 was identified as a novel putative target gene of peroxisome proliferator-activated receptor (PPAR) α by comparing hepatic mRNA expression in wild-type and PPARα-null mice using microarrays; G0s2 mRNA levels were highest in adipose tissue and were upregulated during adipogenic differentiation of preadipocytes, and G0s2 was found to be a direct target gene of PPARs, especially PPARγ. 18 Recently, it was revealed that G0s2 inhibits adipose triglyceride lipase (ATGL), 19 which is the rate-limiting enzyme for triglyceride hydrolysis in adipocytes. 20 In addition, G0s2 has been shown to be a major hepatic lipase that regulates triglyceride turnover. [21] [22] [23] Hepatic expression of G0s2 was markedly increased in Nagoya-Shibata-Yasuda mice fed a high-sucrose diet. 24 Wang et al. 25 reported that adenovirus-mediated expression of G0s2 (AdG0s2) potently induced hepatic steatosis in mice. 25 Together, these studies suggest that G0s2 has an important role in the regulation of hepatic triglyceride metabolism. However, the role of G0s2 in insulin signaling is unclear.
In the present study, male Wistar rats were fed a high-fat diet (HFD) to investigate the effect of hepatic G0s2 on insulin sensitivity after overexpression of G0s2 using Ad-G0s2.
Methods

Plasmid construct of mouse G0s2
Mouse full-length G0s2 cDNA (312 bp; GenBank Accession no. BC117038) was amplified from mouse liver using the primers 5 0 -CAGATGGAAAGTGTG-CAGGAGCTG-3 0 (sense) and 5 0 -CCGGCCTTAA-GAGGCGTGCTGCCG-3 0 (antisense) and subcloned into pCR2.1-TOPO (Invitrogen Life Technologies, Carlsbad, CA, USA). The construct was sequenced to confirm that it was correct.
Construction of recombinant adenoviruses
The Ad-mouse G0s2 was generated from the full-length cDNA, subcloned using an AdEasy Adenoviral Vector System (Stratagene, La Jolla, CA, USA), propagated in HEK293 cells, and purified with Adeno-X Virus Purification and Rapid Titer Kits (Takara Bio, Shiga, Japan). Adenovirus-expressing green fluorescent protein (Ad-GFP; control) was generated using the same procedure (Stratagene, La Jolla, CA, USA). Both recombinant viruses were dialyzed in phosphate-buffered saline (PBS), pH 7.4, and stored in 10% glycerol-PBS at −80 C until use.
Animal studies
Six-week-old male Wistar rats (Charles River Laboratory Japan, Kanagawa, Japan) were housed individually under controlled conditions (12-h light-dark cycle; temperature 25 C), with free access to water and either normal chow diet (NCD) or 60% HFD ((#D12450B and #D12492, respectively; Research Diets, New Brunswick, NJ, USA) for 4 weeks. Rats were provided with fresh diet every 3 days, and the rate of food consumption and body weight gain was monitored every 3 days. After feeding with indicated chow for 3 weeks, rats were implanted with three catheters (0.033 cm outer diameter, 0.014 cm inner diameter; MicroRenathane MRE-033; Braintree Scientific, Braintree, MA, USA), as described previously. 26 Briefly, two catheters were placed in the right jugular vein and the third catheter was placed in the left carotid artery under single-dose anesthesia using pentobarbital (50 mg/kg, i.p.; Kyoritsu Pharmaceutical, Tokyo, Japan). The catheters were tunneled subcutaneously, exteriorized at the back of the neck, and filled with heparinized saline. The jugular and carotid catheters were used for infusion and blood sampling, respectively. Subsequently, injections of 1 × 10 9 plaque-forming units (p.f.u.) G0s2 or GFP viruses per rat were administered intra-arterially via the catheter in the left carotid artery. Rats were allowed 7 days to fully recover from surgery. All procedures were performed in accordance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health (NIH; Bethesda, MD, USA; https:// www.nap.edu/catalog/12910/guide-for-the-care-and-useof-laboratory-animals-eighth, accessed 17 Sep 2017), and were approved by the Animal Subjects Committee of Fukushima Medical University, Fukushima, Japan.
Glucose tolerance tests and euglycemic-hyperinsulinemic clamp
On Day 7 after Ad injection, glucose tolerance and insulin sensitivity were assessed using an intravenous glucose tolerance test (ivGTT) and euglycemichyperinsulinemic clamp. Rats were fasted for 8 h before the start of all experiments.
For the ivGTT, rats were injected with 0.5 g/kg dextrose (50% dextrose; Otsuka Pharmaceutical, Tokushima, Japan) in the jugular vein, as described previously. 27 The euglycemic-hyperinsulinemic clamp experiments began with a constant infusion (0.04 μCi/min) of D- [3- 3 H] glucose (New England Nuclear, Boston, MA, USA). After 120 min tracer equilibration and basal sampling at times −10 and 0 min, glucose (50% dextrose, variable infusion; Otsuka Pharmaceutical) and tracer (0.12 μCi/min) plus insulin (25 mU/kg per min; Novolin R; Novo Nordisk, Copenhagen, Denmark) were infused into the jugular vein, as described previously. 27, 28 Blood samples (60 μL) were drawn at 10-min intervals and analyzed immediately for glucose (Compact Electrode Blood Sugar Analyzer Antsense; Horiba, Kyoto, Japan) to maintain the integrity of the glucose clamp throughout the duration of the experiment. Blood samples were taken at −120 (start of the experiment) and −10 min before infusion and then at 0 (basal), 100, 110 and 120 min (end of experiment) after the start of infusion for determination of glucose specific activity and insulin content. All blood samples were centrifuged for 10 min at 13 000 g at 4 C immediately, and plasma was stored at −80 C until subsequent analysis. After terminal blood sampling at 120 min, rats were killed with an overdose of pentobarbital (180 mg/kg). Tissues (liver, red quadriceps muscle, and white adipose tissue) were collected, immediately frozen in liquid nitrogen and stored at −80 C until subsequent metabolic analysis.
Analytical procedures
Rat insulin, human insulin, glucagon, adiponectin, free fatty acid (FFA), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transpeptidase (γ-GT) were analyzed by a private laboratory (SRL Laboratories, Tokyo, Japan). Plasma glucose specific activity was measured in duplicate after zinc sulfate and barium hydroxide deproteinization. 29 
Immunoblotting analysis
As noted above, the liver, red quadriceps muscle, and white adipose tissue were harvested from rats immediately after they had been killed and were used for metabolic analyses. The specimens were rinsed several times in cold saline to remove blood, frozen in liquid nitrogen, and stored at −80 C. Care was taken to avoid harvesting sections of liver lobes containing large blood vessels. Prior to analysis, tissues were homogenized in liquid nitrogen and lysed in a buffer containing phosphatase and protease inhibitors (Complete Mini; Roche Applied Science, Mannheim, Germany), according to the manufacturer's instructions. Tissue protein concentrations were determined by the bicinchoninic acid (BCA) protein assay, using the BCA reagent (Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of protein were separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Immobilon; Millipore, Bedford, MA, USA), which were then blocked with ImmunoBlock (DS Pharma Biomedical, Osaka, Japan) overnight at 4 C. The membranes were first probed with primary Akt and phosphorylated (p-) Akt (Ser 473 ) antibodies (Cell Signaling Technology, Danvers, MA, USA), followed by probing with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX, USA). The immunocomplexes were visualized using enhanced chemiluminescence (ECL) western blotting detection reagents (Amersham; GH Healthcare, Buckinghamshire, UK). β-Actin served as an internal control protein. Band intensities were quantified by densitometry using ImageJ software (NIH, Bethesda, MD, USA).
Histological examination
A portion of liver was fixed with 10% formalin and embedded in paraffin. Sections (3 μm) were cut and stained with hematoxylin and eosin (H&E) for examination of liver histology (BX-50; Olympus, Tokyo, Japan). The sections were also incubated with anti-G0s2 antibody (#sc-133424; Santa Cruz Biotechnology) for 12 h at 4 C, anti-rabbit secondary antibody, and diaminobenzidine (DAB) using the VECTASTAIN ABC Kit (Vector Laboratories, Burlingame, CA, USA). Slides were counterstained with H&E. To examine lipid accumulation and liver fibrosis, 6-μm frozen sections were stained with Oil Red O. Ten fields in every individual section were selected at random and the Oil Red O-stained area and total tissue area were measured using ImageJ software. The ratio of the Oil Red O-stained area to total tissue area was calculated and is given as a percentage.
Statistical analysis
Homeostasis model assessment of insulin resistance (HOMA-IR) values were calculated from fasting concentrations of insulin and glucose using the following formula:
where FINS is fasting plasma insulin and FPG is fasting plasma glucose. The glucose infusion rate (GIR) required to maintain euglycemia reflects systemic insulin sensitivity. Hepatic glucose output (HGO), which reflects hepatic insulin sensitivity, and glucose disposal rate (GDR) were calculated for the basal period and steady state portion of the glucose clamp using the Steele equation for steady state conditions: 30 
HGO = GDR -GIR
The insulin-stimulated GDR (IS-GDR) reflects the ability of insulin to increase GDR above basal values, which means that the IS-GDR reflects muscle insulin sensitivity. The IS-GDR is calculated by subtracting each animal's basal HGO value from the final GDR achieved at the end of the clamp period as follows:
IS-GDR = Total GDR -Basal HGO Data are presented as mean AE SEM. The significance of differences between two groups was calculated by unpaired Student's t-test. All data were tested for normal distribution to ensure that the use of mean values and t-tests was appropriate. Statistical significance was defined as two-tailed P < 0.05.
Results
Basal levels of G0s2 protein in the liver, skeletal muscle, and white adipose tissue
The expression of G0s2 protein was first investigated in the liver, skeletal muscle, and white adipose tissue of rats fed the NCD or HFD for 4 weeks using western blot analysis. In the liver and white adipose tissue, G0s2 protein levels were significantly higher in rats fed the HFD than NCD (Fig. 1a) . However, there was no significant difference in G0s2 protein levels in skeletal muscle between the NCD-and HFD-fed groups (Fig. 1a) .
To confirm G0s2 protein expression by Ad-G0s2, western blotting analysis was performed on cell lysates obtained from either Ad-G0s2-or Ad-GFP-infected HEK293 cells. Expression of G0s2 protein was detected in cells infected with Ad-G0s2, but not in cells infected with Ad-GFP (Fig. 1b) .
That intra-arterial administered Ad was targeted to the liver was confirmed, with virus-encoded protein expressed in more than 90% of hepatocytes (Fig. 2a) , but not other major endocrine organs such as the pancreas, white adipose tissue, or skeletal muscle (Fig. 2b) , as evidenced by GFP expression. Representative results of immunohistochemistry for hepatic G0s2 protein in rats infected with Ad-G0s2 or Ad-GFP are shown in Fig. 2c . Staining for G0s2 protein was localized to the cytoplasm of hepatocytes. In addition, G0s2 protein levels in Ad-G0s2-infected liver tissues were determined by western blot analysis, which showed that G0s2 protein levels were higher in liver tissues from rats infected with Ad-G0s2 than Ad-GFP (Fig. 2d) .
Overall animal characteristics
Some of the general characteristics of HFD-fed rats in the basal state on Day 7 after injection of Ad-G0s2 or control Ad-GFP are given in Table 1 . There was no significant difference in body weight, liver weight, and food intake between the Ad-G0s2 and control Ad-GFP groups (data not shown). In addition, there were no significant differences in glucose, insulin, and HOMA-IR levels between the two groups, or in adiponectin, FFA, TG, TC, HDL-C, AST, ALT, and γ-GT levels (Table 1) . However, glucagon levels were significantly increased in Ad-G0s2-compared with Ad-GFP-infected rats (Table 1) .
Intravenous glucose tolerance tests
Seven days after the injection of Ads, ivGTTs were performed on HFD-fed rats that had been fasted for 8 h and had been injected with glucose (0.5 g/kg) in the jugular vein. As seen in Fig. 3a , fasting glucose levels did not differ significantly between the Ad-G0s2-and Ad-GFP-infected rats. However, after glucose infusion, glucose levels were significantly higher in Ad-G0s2-than Ad-GFP-infected rats at both 15 min (283.3 AE 11.4 vs 244.9 AE 10.7 mg/dL, respectively) and 30 min (226.2 AE 9.4 vs 195.9 AE 8.7 mg/dL, respectively; P < 0.05 for all; Fig. 3a ). In contrast with expectations, fasting and ivGTT insulin levels did not differ significantly between the two groups (Fig. 3B) .
Euglycemic-hyperinsulinemic clamp
To directly examine the metabolic effect of G0s2 protein on insulin sensitivity, HFD-fed rats injected with Ad-G0s2 or Ad-GFP (control) were subjected to euglycemic-hyperinsulinemic clamps at a maximal (25 mU/kg per min) insulin infusion rate. Steady state glucose and insulin levels during the clamp study were similar in the two groups (Table 1) . During this series of experiments, insulin stimulation of whole-body GDR and suppression of HGO was evaluated. The GIR Data are the mean AE SEM. *P < 0.01 compared with Ad-GFPinfected rats. HOMA-IR, homeostasis model assessment of insulin resistance; FFA, free fatty acids; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase.
required to maintain euglycemia decreased significantly in HFD-fed Ad-G0s2 compared with Ad-GFP (control) rats by 16% (from 34.9 AE 2.3 to 29.4 AE 0.8 mg/kg per min; P < 0.05), showing impaired overall insulin sensitivity (Fig. 4a) . To assess the insulin-stimulated component of glucose disposal, IS-GDR was calculated and was found not to differ significantly between the two groups (Fig. 4b) . Basal HGO values were not significantly different between HFD-fed Ad-G0s2 and Ad-GFP (control) rats (9.9 AE 0.6 and 9.5 AE 0.6 mg/kg per min, respectively; Fig. 4c ). During the clamp study, HGO values were significantly higher in HFD-fed AdG0s2-than HFD-fed Ad-AGF-infected rats (6.7 AE 0.5 vs 5.1 AE 0.6 mg/kg per min, respectively; P < 0.05; Fig. 4c ), suggesting that G0s2 protein exacerbates hepatic insulin resistance.
Insulin signaling studies
To assess the potential cellular mechanisms of G0s2-induced impairment of insulin sensitivity, liver, skeletal muscle, and white adipose tissue samples were obtained from rats at the end of the euglycemic-hyperinsulinemic clamp. These samples, which represent the fully insulinized state at the termination of the glucose clamp study, were homogenized and the protein lysates were subjected to immunoblotting. Phosphorylation of Akt (Ser   473   ) , which is the most important molecule of insulin signaling, was determined. Insulin led to a marked stimulation of Akt phosphorylation in the liver, skeletal muscle, and white adipose tissues from control Ad-GFP-injected HFD-fed rats (Fig. 5 ). There were no significant differences in Akt protein levels in the liver, muscle, and white adipose tissue between HFD-fed Ad-G0s2-and Ad-GFP- Figure 4 Euglycemic-hyperinsulinemic clamp study in high-fat diet-fed rats on Day 7 after injection of adenovirus-expressing green fluorescent protein (Ad-GFP; control; n = 8; &squ;) or adenovirus-expressing mouse G 0 /G 1 switch gene 2 (Ad-G0s2; n = 10; &squf;). (a) Glucose infusion rate (GIR), (b) insulin-stimulated glucose disposal rate (IS-GDR), and (c) clamp and basal hepatic glucose output (HGO). Euglycemichyperinsulinemic clamp studies were performed in rats after an 8-h fast. Data are the mean AE SEM. *P < 0.05; **P < 0.01.
infected rats. Conversely, in HFD-fed Ad-G0s2-infected rats, insulin stimulation of Akt phosphorylation at Ser 437 was decreased significantly in the liver by 65% (P < 0.05; Fig. 5a ), but not in the muscle or white adipose tissue (Fig. 5b,c) . It has been reported that hepatic Akt is essential for maintaining whole-body glucose homeostasis and insulin responsiveness, 31 so these results of these experiments suggest that G0s2 exacerbates hepatic insulin resistance.
Histological examination
Macroscopically, livers harvested from Ad-G0s2-and Ad-GFP-infected HFD-fed rats looked the same (Fig. 6a) . To evaluate lipid accumulation, the livers were subsequently sectioned and stained with Oil Red O, which stains neutral lipids (Fig. 6b ). There was a significant 2.5-fold increase in the Oil Red O-stained area in livers from Ad-G0s2-compared with Ad-GFPinfected HFD-fed rats (Fig. 6c) . This suggests that hepatic insulin resistance worsened in Ad-G0s2-infected rats after HFD feeding, and supports the results of the ivGTT, euglycemic-hyperinsulinemic clamp, and western blotting analysis.
Discussion
The results of the present study demonstrate that G0s2 induces lipid accumulation in rat liver and causes the development of hepatic steatosis after HFD feeding. Overexpression of G0s2 impaired total insulin sensitivity by promoting hepatic insulin resistance. These findings suggest that G0s2 is an important regulator of hepatic glycolipid metabolism.
The liver is one of the primary organs responsible for controlling energy homeostasis in mammals. Hepatic ) in the (a) liver, (b) skeletal muscle, and (c) white adipose tissue from high-fat diet-fed rats on Day 7 after injection of adenovirus-expressing green fluorescent protein (Ad-GFP; control; &squ;) or adenovirus-expressing mouse G0s2 (Ad-G0s2; &squf;). Representative blots are shown along with mean (AE SEM) total and phosphorylated (p-) Akt levels in tissues from rats under basal and clamp conditions (n = 6 in all groups). β-Actin was used as an internal control. *P < 0.05. steatosis arises from an imbalance between TG acquisition and removal. The fatty acids used for hepatic TG formation are derived from the diet, de novo synthesis, and adipose tissue. Glucose also promotes lipogenesis by activating the transcription factor carbohydrateresponsive element-binding protein (ChREBP). 32 During fasting, plasma levels of insulin fall, whereas levels of glucagon and epinephrine increase, stimulating TG hydrolysis in adipocytes. The first step in TG hydrolysis is catalysis by ATGL, which is the rate-limiting enzyme. 20 Expression of ATGL is lower in non-adipose tissues, such as the heart, muscle, and liver. 33 In most tissues of ATGL-null mice, ectopic lipid accumulation is increased (21-fold in cardiac muscle, threefold in skeletal muscle, and 2.3-fold in the liver). 34 Recently, it was reported that Ad-mediated knockdown of ATGL produces hepatic steatosis in mice. 21 In addition, it has been reported that Ad-mediated overexpression of ATGL decreases hepatic steatosis in HFD-fed mice. 22 Liver-specific ATGLknockout mice have been shown to have severe progressive periportal and pericentral macrovesicular hepatic steatosis. 23 These studies suggest that ATGL is a major hepatic lipase that regulates TG turnover.
The activity of ATGL is strongly influenced by regulatory proteins. Lass et al. 35 identified comparative gene identification-58 (CGI-58) as a coactivator of ATGL, which is required for efficient lipolysis. In CGI-58-null mice, fat mass is increased and the mice die a few hours after birth, most likely due to a severe skin defect. 36 These studies suggest that CGI-58 is essential for ATGL activation. 36 More recently, Yang et al. 19 identified G0s2, which was first identified as a potential cell cycle regulator, 9 as an inhibitory protein of ATGL. Considering that G0s2 inhibits ATGL activity, inactivation of ATGL may have been involved in modifying insulin resistance in the Ad-G0x2-infected rats in the present study. However, the association between ATGL and insulin resistance is contentious. Haemmerle et al. reported that glucose and insulin tolerance were improved in ATGL-knockout mice fed NCD, 34 whereas Wu et al. 23 reported that there were no differences in results of the GTT and insulin tolerance test (ITT) between liver-specific ATGL-knockout mice fed either the NCD or HFD. Conversely, Ong et al. 22 reported that Ad-mediated overexpression of ATGL improved insulin tolerance after NCD feeding. 22 With regard to G0s2, Wang et al. 25 reported that, during the oral GTT, G0s2 overexpression in the liver significantly improved glucose tolerance in mice fed standard rodent chow, whereas there were no significant differences in glucose levels during the ITT. In these previous studies, Diacylglycerol content in the liver was not assessed, and most studies were performed only with NCD feeding. The previous studies assessed insulin resistance using the GTT or ITT; these methods are indirect methods for the quantification of insulin sensitivity. In the present study, insulin resistance was evaluated using euglycemic-hyperinsulinemic clamps, which is the gold standard for quantifying insulin sensitivity. In the euglycemic-hyperinsulinemic clamp experiments in the present study, whole-body insulin resistance was exacerbated in rats injected with Ad-G0S2, as evidenced by decreased GIR, compared with the Ad-GFP treated group. Moreover, clamp HGO was increased in the G0s2-treated rats and insulin-stimulated Akt phosphorylation in the liver was reduced. Titchenell et al. 37 demonstrated that hepatic Akt signaling downstream of insulin action regulates hepatic glucose. Therefore, the results of the present study suggest that G0S2 contributes to increased hepatic insulin resistance. Hepatic insulin resistance was increased in HFD-fed Ad-G0s2-infected rats compared with HFD-fed Ad-GFP-infected rats, which is consistent with the results of the ivGTT and western blotting analyses. In HFD-fed rats, hepatic levels of TGs, which are derived from chylomicrons, were increased, resulting in the accumulation of lipid droplets. In Ad-G0s2-infected HDF-fed rats, G0s2 inhibited ATGL-mediated TG hydrolysis in droplets and so TG content was increased. At the same time, in the endoplasmic reticulum, TGs were synthesized from DGs, which is part of de novo lipogenesis. 38 The synthesis of TGs from DGs is catalysed by acyl CoA:diacylglycerol acyltransferase (DGAT) enzymes. Wu et al. 23 reported that DGAT2 mRNA was markedly decreased in liver-specific ATGL-knockout mice, which indicates that TG synthesis may be downregulated by some kind of negative feedback mechanism. Then, DG content may be increased in the liver and promote hepatic insulin resistance. However, hepatic DG content is yet to be assessed, and details of the mechanisms by which G0s2 increases hepatic insulin resistance remain to be determined.
In conclusion, G0s2 may promote hepatic insulin resistance by exacerbating hepatic steatosis after HFD feeding. Further investigations are needed to reveal the mechanism by which G0s2 produces insulin sensitivity.
